CA2502413A1 - Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice - Google Patents

Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice Download PDF

Info

Publication number
CA2502413A1
CA2502413A1 CA002502413A CA2502413A CA2502413A1 CA 2502413 A1 CA2502413 A1 CA 2502413A1 CA 002502413 A CA002502413 A CA 002502413A CA 2502413 A CA2502413 A CA 2502413A CA 2502413 A1 CA2502413 A1 CA 2502413A1
Authority
CA
Canada
Prior art keywords
peptide
sample
protein
peptides
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002502413A
Other languages
English (en)
Inventor
Benjamin M. Perryman
Steve M Helmke
Mark W. Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Publication of CA2502413A1 publication Critical patent/CA2502413A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry

Abstract

L'invention concerne des procédés de quantification de protéines ou de peptides, y compris ceux constituant des isoformes étroitement apparentées, par spectrométrie de masse à temps de vol par désorption/ionisation laser assistée par matrice (MALDI-TOF-MS). La mesure de concentrations de protéines <i>in vivo</i> est extrêmement difficile et problématique, et les concentrations de protéines ne se prêtent pas bien à des corrélations avec les taux d'ARNm, norme utilisée par le passé. L'invention comble les lacunes des méthodologies antérieures en tirant parti de la technologie MALDI-TOF-MS et en appliquant celle-ci aux protéines et aux peptides, afin d'obtenir des mesures quantitatives précises <i>in vivo</i> de concentrations de protéines ou de peptides.
CA002502413A 2002-11-01 2003-10-30 Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice Abandoned CA2502413A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42301902P 2002-11-01 2002-11-01
US60/423,019 2002-11-01
US42314202P 2002-11-02 2002-11-02
US60/423,142 2002-11-02
PCT/US2003/034386 WO2004042072A2 (fr) 2002-11-01 2003-10-30 Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice

Publications (1)

Publication Number Publication Date
CA2502413A1 true CA2502413A1 (fr) 2004-05-21

Family

ID=32314470

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002502413A Abandoned CA2502413A1 (fr) 2002-11-01 2003-10-30 Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice

Country Status (6)

Country Link
US (1) US20040119010A1 (fr)
EP (1) EP1556684A4 (fr)
JP (1) JP2006504971A (fr)
AU (1) AU2003301882A1 (fr)
CA (1) CA2502413A1 (fr)
WO (1) WO2004042072A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
AUPS177202A0 (en) * 2002-04-16 2002-05-23 Diakyne Pty Ltd Multi-element screening of trace elements
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
JP4317083B2 (ja) * 2004-06-04 2009-08-19 株式会社日立ハイテクノロジーズ 質量分析方法及び質量分析システム
JP2006078192A (ja) * 2004-09-07 2006-03-23 Shimadzu Corp 生体高分子の質量分析法
US7833725B2 (en) * 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
JP4584767B2 (ja) * 2005-05-17 2010-11-24 ヒューマン・メタボローム・テクノロジーズ株式会社 タンパク質のプロテオーム定量分析方法及び装置
WO2007003343A1 (fr) * 2005-06-30 2007-01-11 Biocrates Life Sciences Ag Appareil et procede d'analyse d'un profil de metabolites
CN1333250C (zh) * 2005-10-20 2007-08-22 复旦大学 一种基于基质辅助激光解吸电离源质谱靶板的蛋白酶解方法
US20080067345A1 (en) * 2006-04-15 2008-03-20 Fenn John B Method for creating multiply charged ions for MALDI mass spectrometry (ESMALDI)
EP1850132A1 (fr) * 2006-04-26 2007-10-31 DKFZ Deutsches Krebsforschungszentrum Procédé de déterminer le rapport de deux peptides ou acides polynucléiques distincts.
WO2008074769A1 (fr) * 2006-12-18 2008-06-26 Covalx Ag Analyse directe d'agrégats de protéines thérapeutiques par spectrométrie de masse
WO2010002911A2 (fr) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Procédés et matériaux pour la surveillance du myélome utilisant la spectrométrie de masse quantitative
WO2010014512A2 (fr) * 2008-07-30 2010-02-04 The Brigham And Women's Hospital, Inc. Préparation de plaques de test pour désorption-ionisation laser assistée par matrice
JP2010117245A (ja) * 2008-11-13 2010-05-27 Fujifilm Corp 質量分析方法
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
JP5837273B2 (ja) * 2009-03-03 2015-12-24 公益財団法人野口研究所 質量分析法用測定試料及びその調製方法
WO2010118243A2 (fr) 2009-04-08 2010-10-14 Genentech, Inc. Utilisation d'antagonistes de il-27 pour traiter le lupus
DE102009033368B4 (de) * 2009-07-16 2023-01-26 Bruker Daltonics GmbH & Co. KG Massenspektrometrische Sepsisdiagnose
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
WO2012027555A2 (fr) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Peptides cd59 glyqués, leur préparation et leurs utilisations
CZ303056B6 (cs) 2010-12-14 2012-03-14 Mikrobiologický ústav AV CR, v.v.i. Zpusob modifikace povrchu pro prekoncentraci fosforylovaných peptidu pro desorpcne-ionizacní techniky hmotnostní spektrometrie
TR201820873T4 (tr) 2011-08-01 2019-01-21 Hoffmann La Roche Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
PL3301177T3 (pl) 2011-11-18 2020-08-24 Alnylam Pharmaceuticals, Inc. ŚRODKI RNAi, KOMPOZYCJE I SPOSOBY ICH ZASTOSOWANIA DO LECZENIA CHORÓB ZWIĄZANYCH Z TRANSTYRETYNĄ (TTR)
EP2780690A4 (fr) * 2011-11-18 2015-12-09 Alnylam Pharmaceuticals Inc Quantification de transthyrétine et de ses isoformes
WO2013079174A1 (fr) 2011-11-28 2013-06-06 Merck Patent Gmbh Anticorps anti-pd-l1 et utilisations associées
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
PL2855528T3 (pl) 2012-05-31 2019-10-31 Hoffmann La Roche Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi pd-1 i antagonistów vegf
CN103969321B (zh) * 2013-01-24 2016-04-20 复旦大学 基于固定化酶原位高效酶解法的蛋白鉴定及质谱成像的方法
JP5706597B2 (ja) * 2013-03-08 2015-04-22 株式会社島津製作所 マトリックスを用いる質量分析法
WO2014162557A1 (fr) * 2013-04-04 2014-10-09 株式会社島津製作所 Procédé de préparation d'un échantillon pour maldi et dispositif associé
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
MY177774A (en) 2013-05-31 2020-09-23 Genentech Inc Anti-wall teichoic antibodies and conjugates
CA2913011A1 (fr) 2013-05-31 2014-12-04 Genentech, Inc. Anticorps anti-acides teichoiques de paroi et leurs conjugues
EA037325B1 (ru) 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
PL3021869T3 (pl) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
JP6673896B2 (ja) 2014-07-15 2020-03-25 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物
WO2016023019A2 (fr) 2014-08-08 2016-02-11 Alector Llc Anticorps anti-trem2 et leurs procédés d'utilisation
KR102480335B1 (ko) 2014-08-18 2022-12-21 벡톤 디킨슨 앤드 컴퍼니 매트릭스 보조 레이저 탈착 이온화를 위한 시료 제조 방법 및 이를 위한 자동화 시스템
AU2015343029B2 (en) 2014-11-05 2021-07-29 Annexon, Inc. Humanized anti-complement factor C1q antibodies and uses thereof
CN107206102A (zh) 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
CN107249642A (zh) 2014-12-03 2017-10-13 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
EP3227337A1 (fr) 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Procédés et compositions de traitement du cancer à l'aide d'antagonistes de l'axe pd-1 et d'antagonistes de hpk1
JP6264275B2 (ja) * 2014-12-12 2018-01-24 株式会社島津製作所 マトリックス膜形成装置
RS62546B1 (sr) 2015-04-07 2021-12-31 Alector Llc Antitela protiv sortilina i postupci za njihovu upotrebu
CN107592812A (zh) 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
EP4209228A1 (fr) 2015-05-22 2023-07-12 Translational Drug Development, LLC Compositions de benzamide et de composé actif et procédés d'utilisation
US11136390B2 (en) 2015-06-12 2021-10-05 Alector Llc Anti-CD33 antibodies and methods of use thereof
WO2016201389A2 (fr) 2015-06-12 2016-12-15 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
US20170029520A1 (en) 2015-06-29 2017-02-02 Genentech, Inc. Compositions and methods for use in organ transplantation
HUE051998T2 (hu) 2015-07-31 2021-04-28 Alnylam Pharmaceuticals Inc Transztiretin (TTR) iRNS készítmények és eljárások azok alkalmazása TTR-asszociált betegségek kezelésére vagy megelõzésére
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
US20180282415A1 (en) 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
EP3359569A2 (fr) 2015-10-06 2018-08-15 Alector LLC Anticorps anti-trem2 et leurs procédés d'utilisation
CN116003596A (zh) 2015-10-29 2023-04-25 艾利妥 抗siglec-9抗体及其使用方法
EP3423493A2 (fr) 2016-03-04 2019-01-09 Alector LLC Anticorps anti-trem1 et leurs méthodes d'utilisation
JP7045990B2 (ja) * 2016-06-24 2022-04-01 株式会社住化分析センター 物理構造の評価方法
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
AU2017363337B2 (en) 2016-11-23 2021-07-01 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2019028292A1 (fr) 2017-08-03 2019-02-07 Alector Llc Anticorps anti-trem2 et leurs procédés d'utilisation
KR20200033798A (ko) 2017-08-03 2020-03-30 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
JP2021508333A (ja) 2017-09-19 2021-03-04 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療用組成物及び方法
CA3075969A1 (fr) 2017-10-10 2019-04-18 Numab Therapeutics AG Anticorps multispecifiques
EP3470426A1 (fr) 2017-10-10 2019-04-17 Numab Therapeutics AG Anticorps multi-spécifique
KR102180624B1 (ko) * 2017-10-11 2020-11-18 주식회사 엘지화학 Maldi 질량분석법을 이용한 고분자의 정량분석방법 및 고분자 정량분석을 위한 maldi 질량분석용 시편의 제조방법
CN111542543B (zh) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 针对pd-l1的抗体及其变体
CN111699198B (zh) 2017-12-28 2023-09-05 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
EP3740507A4 (fr) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et des variants de celui-ci dirigés contre pd-1
KR20200138720A (ko) 2018-03-30 2020-12-10 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
BR112020023844A2 (pt) 2018-05-25 2021-04-13 Alector Llc Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
RU2709625C1 (ru) * 2018-07-02 2019-12-19 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ определения чувствительности неферментирующих бактерий к дезинфицирующим средствам с применением масс-спектрометрии
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
AU2019310597A1 (en) 2018-07-27 2021-03-11 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
KR102362175B1 (ko) * 2018-08-30 2022-02-11 주식회사 엘지화학 Maldi 질량 분석을 이용한 고분자의 상대적 정량분석방법
AU2019370485A1 (en) 2018-11-02 2021-05-13 Annexon, Inc. Compositions and methods for treating brain injury
CA3127935A1 (fr) 2019-01-31 2020-08-06 Numab Therapeutics AG Anticorps multispecifiques ayant une specificite pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procedes d'utilisation
JP2022534889A (ja) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Ｃｄｋ阻害剤を使用した組合せ療法
WO2020240360A1 (fr) 2019-05-24 2020-12-03 Pfizer Inc. Polythérapies à l'aide d'inhibiteurs cdk
CN114787373A (zh) 2019-07-25 2022-07-22 免疫苏醒公司 测量通过效应子进行的细胞介导的杀伤的方法
TW202118512A (zh) 2019-09-12 2021-05-16 美商建南德克公司 治療狼瘡性腎炎之組成物及方法
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP4055031A2 (fr) 2019-11-04 2022-09-14 Alector LLC Molécules de fusion de siglec-9 ecd et leurs méthodes d'utilisation
IL292757A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Tigit antibodies and their uses
CA3158565A1 (fr) 2019-12-05 2021-06-10 Tina SCHWABE Procedes d'utilisation d'anticorps anti-trem2
KR20220127243A (ko) 2019-12-12 2022-09-19 알렉터 엘엘씨 항-cd33 항체의 사용 방법
CN115768794A (zh) 2020-02-24 2023-03-07 艾利妥 抗trem2抗体的使用方法
CA3172451A1 (fr) 2020-04-03 2021-10-07 Robert Paul Procedes d'utilisation d'anticorps anti-trem2
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
WO2022130206A1 (fr) 2020-12-16 2022-06-23 Pfizer Inc. POLYTHÉRAPIES À INHIBITEURS DE TGFβR1
EP4019547A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour il-4r et il-31
WO2022136675A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps se liant à il-4r
EP4019090A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps liant il-4r
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
EP4019546A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps qui se lient à il-31
WO2022140797A1 (fr) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines et utilisations associées
AU2022215847A1 (en) 2021-02-02 2023-08-10 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
CN113009017B (zh) * 2021-02-25 2021-10-08 杭州佰辰医学检验所有限公司 一种基于抗体偶联磁珠富集技术的激素质谱检测方法
AU2022232951A1 (en) 2021-03-10 2023-10-19 Immunowake Inc. Immunomodulatory molecules and uses thereof
CA3213599A1 (fr) 2021-03-15 2022-09-22 Genentech, Inc. Compositions et methodes de traitement de la nephrite lupique
CN117795074A (zh) 2021-08-03 2024-03-29 阿尔尼拉姆医药品有限公司 转甲状腺素蛋白（TTR）iRNA组合物和其使用方法
WO2023081898A1 (fr) 2021-11-08 2023-05-11 Alector Llc Cd33 soluble en tant que biomarqueur pour une efficacité anti-cd33
EP4183800A1 (fr) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
WO2023164516A1 (fr) 2022-02-23 2023-08-31 Alector Llc Méthodes d'utilisation d'anticorps anti-trem2
WO2023214047A1 (fr) 2022-05-06 2023-11-09 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb
WO2024038193A1 (fr) 2022-08-18 2024-02-22 Immunocore Limited Molécules de liaison à domaines multiples
WO2024038198A1 (fr) 2022-08-18 2024-02-22 Immunocore Limited Molécules de liaison à domaines multiples
WO2024038183A1 (fr) 2022-08-18 2024-02-22 Immunocore Limited Molécules de liaison à domaines multiples
US20240092859A1 (en) 2022-08-18 2024-03-21 Immunocore Ltd T cell receptors and fusion proteins thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
DE19624802A1 (de) * 1996-06-21 1998-01-02 Forssmann Wolf Georg Verfahren zum direkten diagnostischen Nachweis von pathogenen, genetisch bedingten Punktmutationen in Proteinen bei Herzerkrankungen durch chemische und physikalische Methoden, besonders der direkten und indirekten Kopplung der Hochdruck-Flüssigkeitschromatographie und der Massenspektrometrie
CA2434699A1 (fr) * 2001-01-17 2002-10-17 Randall W. Nelson Systeme integre a rendement eleve destine a l'analyse de biomolecules
AU2002338614A1 (en) * 2001-04-17 2002-10-28 Femtolink Biotechnologies Llc Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples

Also Published As

Publication number Publication date
WO2004042072A9 (fr) 2004-08-26
EP1556684A4 (fr) 2008-01-23
EP1556684A2 (fr) 2005-07-27
AU2003301882A1 (en) 2004-06-07
JP2006504971A (ja) 2006-02-09
WO2004042072A3 (fr) 2004-12-29
US20040119010A1 (en) 2004-06-24
WO2004042072A2 (fr) 2004-05-21

Similar Documents

Publication Publication Date Title
US20040119010A1 (en) Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
Cañas et al. Trends in sample preparation for classical and second generation proteomics
Li et al. Single-cell MALDI: a new tool for direct peptide profiling
Laugesen et al. Combination of two matrices results in improved performance of MALDI MS for peptide mass mapping and protein analysis
Bucknall et al. Practical quantitative biomedical applications of MALDI-TOF mass spectrometry
Soares et al. Mass spectrometry and animal science: protein identification strategies and particularities of farm animal species
Wang et al. Improved procedures for N‐terminal sulfonation of peptides for matrix‐assisted laser desorption/ionization post‐source decay peptide sequencing
Tichy et al. Phosphoproteomics: Searching for a needle in a haystack
US7622273B2 (en) Method for chemical and enzymatic treatment of posttranslationally modified proteins bound to a protein chip
Gates et al. Comparison of metal and metal oxide media for phosphopeptide enrichment prior to mass spectrometric analyses
CA3000178C (fr) Detection de beta-amyloide par spectrometrie de masse
Mo et al. Analytical aspects of mass spectrometry and proteomics
WO2005067648A2 (fr) Profilage spatial multiplex d&#39;expression genique
Ocaña et al. BSE Control: Detection of gelatine-derived peptides in animal feed by mass spectrometry
EP1145012B1 (fr) Procedes permettant de sequencer des polypeptides et kits a cet effet
Desiderio Minireview quantitative analytical mass spectrometry of endogenous neuropeptides in human pituitaries
Blacken et al. Reactive landing of gas-phase ions as a tool for the fabrication of metal oxide surfaces for in situ phosphopeptide enrichment
EP2317323A1 (fr) Spectrométrie de masse MALDI (MALDI-MS) pour protéines de poids moléculaire élevé
Padliya et al. A strategy to improve peptide mass fingerprinting matches through the optimization of matrix‐assisted laser desorption/ionization matrix selection and formulation
Burkitt et al. Discrimination effects in MALDI-MS of mixtures of peptides—Analysis of the Proteome
Shen et al. Preparation and characterization of nitrilotriacetic-acid-terminated self-assembled monolayers on gold surfaces for matrix-assisted laser desorption ionization-time of flight-mass spectrometry analysis of proteins and peptides
Thibault et al. MALDI tissue profiling of integral membrane proteins from ocular tissues
US20060211077A1 (en) Methods and compositions to diagnose disease using concatenated oligopeptide standard
Steckel et al. Detection of protein posttranslational modifications by mass spectrometry
Johnson Jr et al. Protein fragmentation via liquid chromatography–quadrupole time-of-flight mass spectrometry: The use of limited sequence information in structural characterization

Legal Events

Date Code Title Description
FZDE Discontinued